Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors
Provided By PR Newswire
Last update: Mar 10, 2025
SOUTH SAN FRANCISCO, Calif., March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich is a medical oncologist and brings more than 25 years of experience developing cellular immunotherapies to treat cancer, including deep expertise in clinical drug development and translational research, and portfolio strategy.
Read more at prnewswire.com
